Moreover, these studies provide experimental evidence that repeat-associated non-ATG translation of repeat-containing sense and antisense RNA leads to dipeptide-repeat proteins (DPRs) that can accumulate and aggregate, indicating that accumulation of DPRs may represent another pathogenic pathway underlying C9 ALS/FTLD. These studies in cell and animal models therefore identify RNA toxicity, RBP sequestration and accumulation of DPRs as emerging pathogenic pathways underlying C9 ALS/FTLD. Abstract GGGGCC (G 4 C 2 ) hexanucleotide repeat expansion in chromosome 9 open reading frame 72 (C9ORF72) has been identified as the most common genetic abnormality in both frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). To investigate the role of C9ORF72-related G 4 C 2 repeat expansion in ALS and FTLD, several animal and cell culture models have been generated that reveal initial insights into the disease pathogenesis of C9 ALS/FTLD. These models include neurons differentiated from patient-derived pluripotent stem cells as well as genetically engineered cells and organisms that knock down C9ORF72 orthologues or express G 4 C 2 repeats. Targeted reduction or knockdown of C9ORF72 homologues in zebrafish and mice so far produced conflicting results which neither rule out, nor confirm reduced expression of C9ORF72 as a pathogenic mechanism in C9 ALS/FTLD. In contrast, studies using patient-derived cells, as well as Drosophila and zebrafish models overexpressing disease-related hexanucleotide expansions, can cause repeat length-dependent formation of RNA foci, which directly and progressively correlate with cellular toxicity. RNA foci formation is accompanied by sequestration of specific RNA-binding proteins (RBPs), including Pur-alpha, hnRNPH and ADARB2, suggesting that G 4 C 2 -mediated sequestration and functional depletion of RBPs are cytotoxic and thus directly contribute to disease.
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Frontotemporal lobar degeneration (FTLD) is a common cause of presenile dementia due to the degeneration of neurons in frontal and temporal lobes, which results in changes of personality, language and behaviour [40] . Amyotrophic lateral sclerosis (ALS) involves degeneration of upper motor neurons in the motor cortex and lower motor neurons of the brainstem and spinal cord, resulting in muscle wasting, weakness and fatality [44] . Approximately 15 % of FTLD patients also have symptoms of ALS and around 50 % of ALS patients also experience symptoms of FTLD, including brain atrophy and cognitive changes [44] . Both disease conditions are characterised by proteinaceous inclusions of the DNA and RNA binding protein Tar DNA binding protein of 43 kDa (TDP-43) [3, 39] . This convergence in clinical presentation, in concert with the significant overlap in disease proteinopathy, indicates that ALS and FTLD are phenotypic variants of common pathological processes at opposite ends of a disease continuum.
In support of this notion, linkage analysis of single kindreds presenting both ALS and FTLD phenotypes [38, 53] , as well as genome-wide association studies (GWAS) in sporadic ALS and FTLD [26, 46, 53] identified a locus on chromosome 9p21 as a potential common cause of ALS and FTLD. Further analysis of the C9p21 locus identified massive expansions of a GGGGCC (G 4 C 2 ) repeat in the first intron of chromosome 9 open reading frame 72, C9ORF72 [16, 21, 43, 47] which accounts for 20-80 % of familial and 5-15 % of sporadic ALS and FTLD in North American and European populations [16, 43] . These findings have therefore identified G 4 C 2 hexanucleotide repeat expansion in C9ORF72 as the most common genetic abnormality in FTLD and ALS.
To investigate the role of C9ORF72-related G 4 C 2 repeat expansion in ALS and FTLD, several animal and cell culture models have been generated that have provided initial insights into G 4 C 2 repeat toxicity. These models include neurons differentiated from patient-derived pluripotent stem cells (iPSNs) as well as genetically engineered cells and organisms that knock down C9ORF72 orthologues, express patient-derived G 4 C 2 repeats or that overexpress synthetic G 4 C 2 repeats of pathogenic length. In the following, we will 1 3 review how these models match molecular, cellular and clinical phenotypes of C9 ALS/FTLD and analyse the emerging pathogenic mechanisms with a focus on how they contribute to our understanding of disease initiation and progression. For a broader view on ALS and FTLD, the reader is referred to excellent recent reviews [31, 44] .
C9ORF2 encodes a conserved DENN protein and is enriched in the nervous system
The C9ORF72 gene comprises 12 exons, including two non-coding exons (1a and 1b). Based on its exon-intron structure, it is predicted to be alternatively spliced to generate three protein-coding mRNA transcript variants: V1 (NM_145005.5), V2 (NM_0183525.3) and V3 (NM_001256054.1), with exons 1a and 1b to be differentially incorporated into RNA (Fig. 1) . The functions of the resulting C9ORF72 protein isoforms are presently unknown. Bioinformatic studies suggest that C9ORF72 belongs to a poorly characterised protein family that is highly conserved throughout evolution, with marked loss or divergences in certain species such as the fruit fly Drosophila. C9ORF72 sub-families exist in protists, demonstrating the presence of this protein in a eukaryotic ancestor common to plants, fungi and animals. Notably, most animals with the exception of insects retain one protein with C9ORF72 sequence convergence, whereas most fungi and plants do not [29, 57] .
C9ORF72 expression is highest in the CNS, with V2 being the major-predicted C9ORF72 transcript. Expression of C9ORF72 is detectable especially in the cerebellum, and also observed in the frontal cortex, hippocampus, hypothalamus and spinal cord [43] . A recent study using transgenic mice showed that increased expression of the transcript that does not harbour the site of repeat expansion is seen in motor neurons and frontal cortex, relative to the other transcripts. Similarly increased expression of the non-repeat-containing transcript is seen in human embryonic stem cell-derived motor neurons [48] . Notably, this study also identified that the mouse C9ORF72 orthologue is most readily expressed in neurons associated with FTLD and ALS, but almost absent in spinal microglia and astrocytes [48] , suggesting that neuron-specific expression patterns of C9ORF72 may explain cell type-specific neurodegeneration. Fig. 1 C9ORF72 encodes members of the DENN protein family with structural and functional homologues in other organisms. a C9ORF72 comprises two non-coding exons, 1a and 1b (grey) and coding exons 2-11 (blue). It is transcribed into three variant premRNAs (V1, V2 and V3). V1 encodes a short C9ORF72 isoform B (NP_659442.2), whereas V2 and V3 encode NP_060795.1 and NP_001242983.1, respectively, both of which are translated into the longer C9ORF72 isoform A. Note: this nomenclature is based on the NCBI database, which has been updated since original papers in 2011. Equally, Ensembl does not recognise V3 but lists another transcript containing non-coding exon 1a and the repeat-containing locus. ◂ Sequence homology identifies C9ORF72 as a member of the highly conserved family of differentially expressed in normal and neoplastic cell (DENN) proteins (Fig. 1) . C9ORF72 orthologues have been identified in C. elegans, zebrafish and mice which are therefore ideal model systems for studying loss of C9ORF72 protein function (Fig. 1b) . Drosophila lacks an obvious C9ORF72 homologue although a strong structural homology is observed between DENN-like proteins (Fig. 1c) , suggesting potential functional homology of C9ORF72 in these organisms. Thus, investigation into altered activity of these proteins will be of interest in models of the C9ORF72 mutation. Interestingly, proteins with DENN regions are evolutionarily conserved Rab guanine-diphosphate/triphosphate exchange factors (Rab-GEFs) that activate Rab-GTPases [29, 57] . GTPases function in vesicular formation and membrane trafficking and are therefore crucial for synapse formation and function [5, 29, 57] . C9ORF72 isoforms A and B have been detected in the membrane fraction of whole-cell lysates from C9+ iPSC-derived motor neurons [45] , suggesting that dysfunctional Rab-GTPases may affect synaptic membrane trafficking in C9 ALS/FTLD. However, experimental data to support such a causal relationship are thus far lacking. (Fig. 2) . Genome sequencing in healthy controls revealed that 95 % of controls have below 30 repeats [47] . The size of G 4 C 2 expansion in ALS and FTLD patients has been estimated by Southern blotting to range between 600 and 2,000 repeats [6, 16] , although the exact number of repeats and hence the precise threshold for disease is still unclear due to difficulties in accurately handling and sequencing DNA with such a high GC content. G 4 C 2 repeats are capable of forming RNA guaninequadruplexes (G-quadruplexes) in vitro, which have the capacity to form unimolecular and multimolecular structures [18, 41] (Fig. 2a) . 5′ UTR G-quadruplexes occur naturally and are implicated in both cap-dependent and capindependent translational initiation as well as translational suppression [9] . Conformational changes within RNA molecules fluctuate with changes in intracellular conditions. Recently, within single RNA molecules, competitive hairpin and G-quadruplex formation have been described that can be altered by metal ion exposure [10] . Thus, whether G 4 C 2 repeats form G-quadruplexes or RNA hairpins in vivo will likely depend on immediate intracellular environment. Similarly, differences in intracellular environment and secondary structure may help explain the cell typespecific toxicity that results from G 4 C 2 repeat expansion in C9ORF72. However, in vivo evidence for G 4 C 2 G-quadruplex formation is currently lacking. G 4 C 2 repeat expansions in ALS and FTLD are associated with cytological alterations that are becoming diagnostic markers for C9 ALS/FTLD. Repeat expansion in C9ORF72 is always associated with TDP-43 proteinopathy but has also been shown to result in mutation-specific features of disease that are not observed in non-carrier ALS and FTLD patients. These features include observation of TDP-43-/ p62+ neuronal intranuclear and cytoplasmic inclusions (NIIs and NCIs) in the cortex, hippocampus and cerebellum [2, 32, 51] . In addition, there is accumulating evidence that pathogenic G 4 C 2 repeat expansion is associated with the sequestration of RNA-binding proteins (RBPs), including heterogeneous nuclear ribonucleoproteins (hnRNPs) ( Table 1 ), suggesting that G 4 C 2 repeat expansion affects RNA processing.
Several hypotheses are emerging about the underlying disease mechanisms leading to cellular toxicity, including reduced or loss of function of the C9ORF72-encoded protein and RNA gain-of-function mechanisms [15, 31] . In addition, the three possible reading frames of G 4 C 2 repeats, and also antisense G 2 C 4 repeats, have been shown to be subject to repeat-associated non-ATG translation (RAN translation) which results in protein synthesis in the absence of an upstream start codon [58] . In the case of G 4 C 2 repeats, RAN translation results in dipeptide-repeat proteins (DPRs) from both the sense and antisense RNA strand, leading to poly-glycine-alanine (GA)/poly-prolinealanine (PA), poly-glycine-proline (GP) and poly-glycinearginine (GR)/poly-proline-arginine (PR) that accumulate in proteinaceous inclusions in brains of C9 ALS/FTLD patients [4, [35] [36] [37] 59] . These data suggest that either in conjunction with, or in parallel to RNA gain-of-function and a potential loss of C9ORF72 function, G 4 C 2 -derived DPRs may act as cytotoxic species. How does experimental evidence from cell and animal model systems support these potential pathogenic pathways?
Does reduced or loss of C9ORF2 function contribute to disease?
Repeat expansion within non-coding regions can cause loss of protein expression through failed translation of mRNA transcripts [42] . This phenomenon is observed in fragile X syndrome (FXS) where CGG expansion beyond a 200 repeat unit threshold in the 5′UTR of FMR1 induces a loss of FMRP expression and subsequent neuronal dysfunction [42] . A similar mechanism is responsible for loss of frataxin function in Friedrich's Ataxia [42] . Haploinsufficiency (reduced protein levels due to one loss-of-function allele) has also been suggested as a potential underlying mechanism for C9ORF72-related neurodegeneration [16] .
Indeed, reduction in total and variant-specific C9ORF72 mRNA has been reported in post-mortem tissue from C9+ patients, including frontal cortex [7, 12, 16, 21] , cerebellum, motor cortex and cervical spinal cord [7, 17, 35] , as well as in patient-derived lymphoblast cell lines [16] , patient-derived iPSNs [17] and in blood samples [55] . In a homozygous mutation carrier, the levels of all three C9ORF72 transcript variants appeared reduced as compared to patients with one expanded C9ORF72 allele [19] . Reduced C9ORF72 mRNA expression in the disease condition may occur through suppression of gene expression via epigenetic changes. Indeed, expanded G 4 C 2 repeats were shown to interact with trimethylated, but not non-trimethylated lysine residues within histones H3 and H4 [8] . C9+ patient-derived fibroblasts treated with a DNA and histone demethylating agent revealed increased C9ORF72 transcript detection in these cells [8] . Expanded G 4 C 2 repeats may also suppress C9ORF72 mRNA expression through hypermethylation of a cytosine-phosphate-guanine (CpG) island upstream of C9ORF72, a phenomenon that was reported in the blood of C9+ patients with repeat expansion greater than 43 repeat units, but not in controls [55] .
In contrast, substantial increases in sense and antisense transcripts containing C9ORF72 intron 1 (the site of the expansion) have been described in C9+ patient cerebellum, relative to controls [37] . Similarly, increased use of exon 1a is seen in C9+ ALS patient-derived iPSNs relative to controls [45] . This indicates that although overall C9ORF72 expression may be reduced in C9+ carriers, transcript variants containing intron 1, or spliced intron 1 fragments, may be stabilised, suggesting that an RNA gain-of-function mechanism could also be at play. Thus, it remains unclear whether G 4 C 2 repeat expansion in C9 ALS/FTLD represents a loss or gain of C9ORF72 function in disease.
To determine whether reduction or loss of C9ORF72 might be causally related to disease, C9ORF72 orthologues have been knocked down in zebrafish, mouse and human cell lines. These data produced contradictory results at two extreme ends, suggesting that C9ORF72 protein is either dispensable or essential for normal nervous system development and function. Morpholino-mediated knockdown of all three transcript variants of zebrafish C9ORF72 resulted in significant shortening and abnormal branching of motor neuron axonal projections, as well as impaired escape and unprovoked swimming behaviour. Although the level of knockdown was not quantified, these phenotypes could be completely rescued by coinjection of human C9ORF72 mRNA, suggesting a direct role of C9ORF72 in the observed phenotypes [12] . Conversely, in another study, knockout of C9ORF72 in zebrafish did not result in axonal defects or impaired motor behaviour (Schmid, Hruscha, Haass, unpublished).
Similar results have been reported in mice where reduction of mouse C9ORF72 transcript across a range of 30-75 % was reported to be well tolerated and did not seem to cause major phenotypic effects [27] . Total transcript reduction to ~75 % of normal levels had no impact on locomotion or anxiety after 17 weeks although data for later stages were not presented. Interestingly, even though these C9ORF72 knockdown mice did not manifest obvious motor abnormalities, reduction of C9ORF72 expression to ~30 % of normal levels resulted in modest alteration of RNA expression profile [27] .
Consistent with a possible mammalian tolerance of reduced C9ORF72 expression is the finding that antisense oligonucleotide (ASO) targeting of exon 2, and therefore knockdown of all C9ORF72 isoforms to ~10 % of residual levels, had no adverse phenotypic impact and actually reversed disease-related alterations in transcriptional profile identified in C9+ ALS patient-derived motor neurons compared to controls [45] . In addition, this study used a commercially available C9ORF72 antibody that recognised both protein isoforms to show that no alteration in C9ORF72 expression level could be observed in C9+ ALS patientderived fibroblasts and motor neurons when compared with controls [45] . Similarly, an independent study reported that altered expression of only 6 genes was observed following knockdown of C9ORF72 to ~10 % of normal levels in healthy control-derived fibroblasts. Importantly, this expression profile was markedly different to that in C9+ patientderived fibroblasts, in which 122 genes were upregulated and 34 were downregulated relative to control and sporadic ALS fibroblasts [27] ; however, the functional relevance of these transcriptional alterations remains to be determined. These data collectively suggest that severe reduction in C9ORF72 expression is insufficient to capture diseaserelated phenotypes identified from patient-derived tissue.
Taken together, the available studies so far neither rule out, nor confirm reduced expression of C9ORF72 as a pathogenic mechanism in C9 ALS/FTLD. In this context, it should be noted that pathogenic coding mutations of C9ORF72 have not been found yet [22] , and homozygosity for the expanded-repeat allele does not seem to confer an increasingly severe disease phenotype, which would be expected if the disease mechanism relied on C9ORF72 loss of function [19] . Instead, in the presence of the G 4 C 2 repeat expansion, differential use of exon 1a and exon 1b has been reported (Fig. 2a) , which suggests that levels of repeat expansion-containing transcript may actually be enhanced in C9 ALS/FTLD, consistent with a gain of function disease mechanism.
G 4 C 2 -related RNA toxicity contributes to C9 ALS/FTLD
Loss of protein function is a feature of many repeat expansion disorders but often does not explain the full extent of toxicity observed [8] . In diseases such as Myotonic Dystrophy type 1 and 2 (DM1 & DM2) and Fragile X Tremor/ Ataxia Syndrome (FXTAS), the major pathogenic function of repeat-expanded RNA arises from the formation of nuclear RNA foci [14, 33, 54] . Expansion of repeat sequences promotes formation of hairpin structures within pre-mRNA and mRNA molecules, which in turn can lead to aggregation of mutated RNA and sequestration of RNAbinding proteins (RBPs) into these foci [49] . Among other Disease-related hexanucleotide repeat expansions are considered to be >30 repeats. G 4 C 2 repeat-containing genomic DNA is transcribed in the sense and antisense directions, yielding pre-mRNA containing both G 4 C 2 and G 2 C 4 repeat expansions. Sense RNA is considered to form RNA hairpins, as well as unimolecular or multimolecular G-quadruplexes (depicted). b Both sense and antisense hexanucleotide repeat RNA can lead to the formation of intranuclear RNA foci. These RNA foci have been demonstrated to interact with and colocalise with RNA-binding proteins (RBPs) and hnRNPs, including hnRNPA1, Pur-alpha, ADARB2 and hnRNP H. Sequestration of RBPs and hnRNPs can affect RNA processing and alter expression of target genes, ultimately causing cytotoxicity. c Both sense and antisense hexanucleotide repeat RNA can be subject to repeat-associated non-ATG (RAN) translation leading to DPRs polyglycine-alanine (GA), poly-glycine-proline (GP) and poly-glycinearginine (GR) as well as poly-proline-arginine (PR) and poly-prolinealanine (PA). These DPR species have been shown to accumulate and aggregate in C9 ALS/FTLD cases. Thus, accumulation of sense and antisense DPRs suggests that RAN translation of the repeat sequence occurs following cytoplasmic export of repeat-containing RNA to the cytoplasm, producing potentially cytotoxic GP, GA, GR, PA and PR inclusions effects, foci-bound RBPs are unable to regulate their RNA targets, including alternative splicing of pre-mRNAs, leading to diminished cellular viability [42, 49] . Hence, formation of RNA foci and resultant RNA metabolism abnormalities are well-characterised mechanisms for trinucleotide repeat-related RNA diseases as seen in DM1&2 as well as in FXTAS. Notably, the available studies on G 4 C 2 -related neurodegeneration suggest that C9 ALS/FTLD hexanucleotide repeat expansion shares similarities with these other RNA diseases. G 4 C 2 repeat length-dependent formation of RNA foci and apoptotic cell death RNA foci were first observed in the frontal cortex and spinal cord of C9+ patients [16] and numerous studies have now presented evidence for both sense and antisense intranuclear RNA foci in disease-relevant CNS regions of C9+ patients, including frontal cortex, cerebellum, hippocampus, and spinal neurons as well as in non-neuronal cells [20, 27, 34, 59] . Interestingly, a significant correlation between RNA foci burden and age of disease onset has been reported, suggesting that increased RNA foci load may directly correlate with disease pathogenesis [34] . This is further supported by experimental data, which demonstrate that RNA foci form in C9+ patient-derived fibroblasts but also in iPSNs, as well as in transgenic cells, Drosophila and zebrafish that express G 4 C 2 longer than 30 repeats (Fig. 2b) .
Thus, in C9+ patient-derived cells, up to 90 RNA foci of 0.2-0.5 μm were observed predominantly in the nucleus, with occasional cytoplasmic foci. G 4 C 2 -related RNA foci formation was substantiated in neurons derived from C9+ iPSCs, which formed functional synaptic connections in culture and were capable of firing action potentials [1, 45] . Interestingly, the presence of G 4 C 2 repeat expansion did not affect neuronal differentiation of C9+ iPSC-derived neurons, nor did it seem to alter C9ORF72 mRNA levels [1] . Moreover, fluorescence in situ hybridisation (FISH) labelling with probes designed to recognise exons or introns either upstream or downstream of the repeat sequence did not reveal nuclear foci, suggesting that these exonic/intronic sequences are degraded. In contrast to controls, motor neurons derived from C9+ ALS fibroblasts were characterised by an increased number of transcripts containing exon 1a at the expense of transcripts containing exon 1b, suggesting that presence of the repeat expansion causes a toxic RNA gain-of function mechanism [45] .
Repeat length-dependent formation of RNA foci has also been observed in numerous cell types, primary neurons and zebrafish embryos ectopically expressing G 4 C 2 sequences. RNA foci were observed with a repeat length of 38 (~6 foci per cell) or 72 (~12 foci per cell), but not with 8 repeats in neuronal and non-neuronal cells. Using the same 8x, 38x and 72x G 4 C 2 repeats inserted in the 3′UTR of EGFP, nuclear retention of 38x and 72x was observed in cells containing RNA foci, suggesting apoptotic cell death [28] . Moreover, increased annexin V and caspase-3 activation were detected in RNA foci-containing cells. While HEK293 cells did not show elevated levels of caspase-3, poly(ADP-ribose) polymerase (PARP) cleavage was detected in 38x-and 72x-expressing human neuroblastoma SH-SY5Y cells, suggesting that neuronal cell populations are more susceptible to repeat RNA-mediated apoptosis than other cell types [28] . Comparable findings were obtained by expressing transgenic constructs containing either EGFP as control, EGFP with 3x G 4 C 2 or with 15xG 4 C 2 -CTCGAG-15xG 4 C 2 (15x+15x) inserted at the 5′ end, respectively. These constructs, when expressed in mouse neuroblastoma Neuro-2a cells caused a significant decline in cellular viability only with the 15x+15x construct [56] , suggesting a progressive correlation between repeat length and cellular toxicity.
Indeed, two in vivo animal studies provide further evidence for repeat length-dependent RNA foci and progressive cell death. Transgenic Drosophila overexpressing 3x G 4 C 2 or with 15xG 4 C 2 -CTCGAG-15xG 4 C 2 (15x+15x) revealed that cell type-specific overexpression of the 15x+15x but not the 3x or 0x construct was sufficient to induce age-related neurodegeneration in photoreceptors of the fly eye (GMR-Gal4), and when overexpressed in motor neurons (OK-371-Gal4), which resulted in age-related locomotor deficits. Moreover, overexpression in all neurons resulted in larval lethality. However, whilst it seems clear that the 15x+15x construct could trigger toxic phenotypes not observed with any 3x or 0x lines, the authors do not precisely report on expression levels or differing phenotypes between various 15x+15x lines, leaving a question mark over how much of the observed phenotypes result from the G 4 C 2 repeat sequence itself and how much depends on genomic location of transgene insertions or RNA/protein load which in itself can cause nonspecific neurodegeneration [23] . Nevertheless, comparable findings were observed in vivo using transgenic zebrafish embryos, where expression of 38x and 72x G 4 C 2 repeats increased the number of apoptotic cells, relative to 8x repeats as measured by DNA fragmentation using TUNEL assay. RNA foci were only observed in embryos expressing 72x G 4 C 2 repeat, and cells positive for RNA foci were also characterised by caspase-3 activity and condensed and fragmented nuclei [28] .
Taken together, experimental evidence from cell and animal models suggests that expression of G 4 C 2 hexanucleotides can cause repeat length-dependent formation of RNA foci which directly and progressively correlate with cellular toxicity that is mediated by caspase-dependent cell death.
G 4 C 2 repeats bind and sequester RBPs which correlates with cytotoxicity
To gain insights into the pathogenic mechanisms underlying repeat-mediated toxicity, several pulldown experiments have been carried out to identify interacting partners of G 4 C 2 repeats [36, 56] . All studies thus far have consistently identified RBPs including hnRNPs as the major interacting proteins of G 4 C 2 repeats (see Table 1 ), thereby revealing a striking similarity to other nucleotide repeat expansion diseases [13, 49] .
In vitro-transcribed biotinylated RNA containing G 4 C 2 or control A 4 C 2 repeats incubated with nuclear protein extracts identified several RBPs involved in RNA metabolism, translation and transport [36] . Subsequent analysis of human autopsy brains revealed that one of the identified targets, hnRNPA3, co-localised with p62-positive/TDP-43-negative neuronal cytoplasmic and intranuclear inclusions in the hippocampus of patients with C9ORF72 repeat expansions. The presence of hnRNPA3 in these inclusions, in addition to the identification of a host of other hnRNPs including hnRNPA2/B1, hnRNPR, hnRNPL, hnRNPA1 and hnRNPK as binding partners of G 4 C 2 repeats in vitro (Fig. 2b) , suggests that RBP sequestration and subsequent misregulation of their targets could lead to neurodegeneration.
Pull-down experiments using mouse brain lysate and biotinylated G 4 C 2 repeats as bait also identified several hnRNPs, including hnRNPsH1 and H2 [1] . Immunocytochemical analysis of C9+ ALS iPSC-derived neurons identified colocalisation of RNA foci with hnRNPA1 and Pur-alpha, but produced negative results for hnRNPA3, hnRNPA2/B1, TDP-43 or FUS [1, 45] as well as for nucleophosmin and hnRNPF [1] . Another study using C9+ iPSNs did not reveal an increase in nuclear foci containing Pur-alpha, p62, hnRNPA1, hnRNPA1B2, FUS, and TDP-43, whereas the adenosine deaminase ADARB2 was demonstrated to interact with C9ORF72 RNA and to have a high-binding affinity to G 4 C 2 RNA [17] .
The interaction between ADARB2 and G 4 C 2 repeats was shown to be important for the maintenance or formation of RNA foci following a study in which siRNA-mediated knockdown of ADARB2 resulted in a ~50 % decrease in the number of iPSNs containing RNA foci. Moreover, a time-and dose-dependent 100-fold increase in glutamateinduced cell death was observed in C9+ iPSNs compared to control iPSNs. Blockage of this phenotype through treatment with inhibitors of glutamate receptors and calcium channels confirmed that the nature of this effect was glutamate receptor dependent. A 50 % reduction in ADARB2 RNA was capable of increasing the glutamate susceptibility of control iPSNs to the levels observed in C9+ iPSNs [17] .
Related to these functional studies, a candidate-binding protein approach identified colocalisation of hnRNPH, SF2 and SC35 with RNA foci in SH-SY5Y cells, with hnRNPH showing almost complete overlap with the foci. hnRNPH (but not SF2 or SC35) was pulled down from SH-SY5Y nuclear lysate and rat brain nuclear lysate using G 4 C 2 probes, confirming that this protein interacts directly with the repeat sequence. shRNA knockdown of hnRNPH achieved knockdown to 95 % of normal levels in SH-SY5Y cells, which resulted in a significant decrease in the inclusion of exon 7 into TARBP2, a target of hnRNP used as a reporter of its splicing activity. G 4 C 2 72x SH-SY5Y experienced a more modest decrease in exon 7 inclusion in TARBP2, consistent with the hypothesis that G 4 C 2 RNA Table 1 Interaction of G 4 C 2 repeats with RBPs and hnRNPs RNA-binding proteins (RBPs) and heterogeneous nuclear ribonucleoproteins (hnRNPs) that have been shown to directly bind G 4 C 2 repeats and mislocalise in RNAi foci in both C9 ALS/FTLD patient-derived post-mortem tissue and in related disease models. Disease-related phenotype refers to cytological alterations or rescue experiments which indicate that misexpression of these proteins can alter disease-related phenotypes. See text for details ND not determined a Small colocalisation of hnRNPA2/B1 is observed in one study [45] , whereas other studies do not report co-localisation [17, 28] b hnRNPH is observed in a cellular overexpression model [28] whereas another study did not observe mislocalisation of hnRNPH1 and hnRNPH2 in C9+ iPSNs [1] foci may sequester and deplete hnRNPH levels, resulting in modified splicing of its targets. Importantly, FISH analysis of human post-mortem brains confirmed abundant RNA foci in the cerebellum with less abundant foci observed in frontal and temporal cortices of ALS and FTLD patients [28] , while other studies reveal that RNA foci are most abundant in cortex and less abundant in cerebellum [27, 34] . Cerebellar intranuclear RNA foci size ranged from 200 to 500 nm and frequently (~70 %) colocalised with hnRNPH [28] , suggesting a direct role of RBP sequestration in cellular toxicity. In addition, experiments in transgenic flies as well as a pull-down assay from human frontal cortex identified Puralpha as the most abundant protein binding G 4 C 2 repeats [56] . Significantly, coexpression of a toxic 15x+15x G 4 C 2 repeat construct affecting cell viability with Pur-alpha was able to reverse cell viability; this rescue was not observed with co-expression of hnRNPA2/B1. Similarly, siRNAmediated knockdown of Pur-alpha in Neuro-2a cells caused reduced cell viability, confirming that a reduction in Puralpha expression is toxic to cells. In addition, concomitant overexpression of Pur-alpha with 15x+15x G 4 C 2 repeats in the fly eye rescued the neurodegenerative phenotype caused by this construct expressed alone [56] .
Taken together, experimental evidence from C9+ patient-derived iPSNs, transfected cells and transgenic Drosophila suggest that direct binding of a specific subset of RBPs and hnRNPs to disease-related G 4 C 2 repeats and their sequestration into RNA foci might be causally related to cellular toxicity and apoptotic cell death (Fig. 2) . It remains to be shown whether the sequestration of RBPs directly triggers the apoptotic machinery, or whether it is a secondary effect of mitigated or failed RNA metabolism, translation and transport dependent on normal RBP function. Moreover, it will be interesting to see whether and which of the identified hnRNPs confer cellular specificity observed in C9 ALS/FTLD-related neurodegeneration.
Other identified targets of G 4 C 2 unrelated to RBPs Consistent with the RBP sequestration hypothesis, several other alterations have been identified in C9 ALS/FTLD disease models that may reveal insights into pathogenesis. Transcriptome analysis of C9+ ALS fibroblasts and iPSNs revealed unique alterations when compared with healthy controls and SOD1 D90A iPSN lines [17] . Comparison of these genes with those identified in a similar study using C9+ motor cortex identified 41 common upregulated genes and 212 common downregulated genes. 7 of these genes (EDN1, NEDD4L, FAM3C, CHRDL1, CP, SEPP1, SER-PINE2) were identified as having the same direction of misregulation in C9+ iPSNs and C9+ motor cortex/spinal cord samples, following an initial selection of 26 genes that may be useful as biomarkers [17] . Other identified genes include DPP6, a GWAS-identified gene associated with sporadic ALS and involved in regulation of membrane excitability, KCNQ3, the interacting potassium channel and three members of the cerebellin (CBLN1, CBLN2 and CBLN4) family of proteins involved in synapse formation [45] . Overexpression of the Drosophila homologue of KCNQ3 has previously been shown to reduce neuronal excitability [11] , suggesting that alterations in synaptic transmission may play a role in neurodegeneration. Indeed, C9+ ALS patient-derived motor neurons exhibit decreased excitability (fewer spikes upon depolarisation), a phenomenon to which the observed increase in KCNQ3 expression in these neurons may contribute [45] .
Does DPR aggregation contribute to C9 ALS/FTLD?
A recent study into polyglutamine toxicity in Spinocerebellar Ataxia Type 8 (SCA8) and myotonic dystrophy type 1 (DM1) found that CTG repeat sequences can be translated in the absence of an upstream AUG codon [58] . This phenomenon, termed repeat-associated non-ATG (RAN) translation, has since been reported as a feature of all noncoding repeat expansion disorders, with a direct role in neurodegeneration reported in a recent Drosophila model of FXTAS [50] .
First evidence for RAN-translated G 4 C 2 -derived DPRs came from studies using antibodies against poly-glycine-alanine (GA), poly-glycine-proline (GP) and polyglycine-arginine (GR) which revealed the presence of neuronal cytoplasmic inclusions in the cerebellum, hippocampus, neocortex, sub-cortical grey matter and brainstem of C9+ FTLD/ALS patients but not in controls [4, 37] . These inclusions share morphology and distribution with TDP-43-, p62+, ubiquitin/ubiquilin-2+ inclusions that are a pathognomonic feature of patients harbouring repeat expansion in C9ORF72 [2] . Interestingly, immunohistochemical studies were able to establish the presence of DPRs predicted to derive from antisense RAN translation, poly-proline-arginine (PR) and poly-proline-alanine (PA), which were detected in inclusions in diseaserelevant tissue, specifically in C9+ patients [20, 35] . The presence of DPRs provides evidence that RAN translation takes place in both sense and antisense directions, producing potentially toxic GP, GA, GR, PA and PR inclusions. Significantly, DPRs RAN-translated from both sense and antisense strands have been detected within the cytoplasm of hippocampal neurons of C9+ ALS/FTLD patients, but not in neurons of C9− ALS patients or healthy controls [59] .
Whilst inclusions containing DPRs from sense and antisense RAN translation are now a well-established pathological feature of C9+-specific ALS/FTLD, it remains unclear if and how the products of RAN translation play a toxic role in disease progression. Patient-derived and transgenic model systems have recently been developed that demonstrate DPR accumulation and have already provided initial insights into a potential pathogenic role of these protein species.
In C9+ patient-derived iPSNs, immunoblotting [1] and immunofluorescence [17] detected the presence of poly-GP proteins. Significantly, the abundance of poly-GP signal was observed to be independent of RNA foci load and repeat length in these C9+ patient-derived iPSNs [1] . Moreover, G 4 C 2 -derived DPRs were not observed in a C9+ patient-derived iPSN culture containing specifically motor neurons [45] . In contrast, a recent transfected non-neuronal cell model revealed that increasing levels of cytoplasmic DPRs correlate with increased cellular toxicity [59] . In this study, transfected HEK293 cell lines were generated each containing 80x C 4 G 2 , or G 4 C 2 , repeats either in the presence or absence of an upstream ATG start codon in the reading frame necessary for translation of poly-PR or poly-GP proteins, respectively. As a result, increased poly-PR and poly-GP protein were detected, suggesting that levels of poly-PR and poly-GP proteins could potentially be enhanced by antisense ATG-initiated translation of the expanded repeat sequence [59] . These data are of clinical relevance as ATG start codons are found upstream and inframe for antisense GP and PR translation within human C9ORF72. Since increased levels of poly-PR and poly-GP correlate with decreased cellular viability [59] , these data suggest that DPR accumulation may cause cytotoxicity.
Taken together, pathological evidence as well as experimental data provide unambiguous evidence that sense and antisense DPRs are translated from repeat-containing RNA (Fig. 2c) . Notably, these studies provide initial evidence that accumulation of RAN translated DPRs can lead to DPR aggregation, which correlates with cellular toxicity, indicating that accumulation of DPRs may represent one of the pathogenic pathways underlying C9 ALS/FTLD.
Emerging pathogenic pathways underlying C9 ALS/FTLD relate to other repeat expansion diseases
Since the discovery of G 4 C 2 hexanucleotide repeat expansions in C9ORF72, several cell and animal models have been generated to gain insights into C9ORF72-related ALS and FTLD. These models neither rule out nor confirm reduced expression of C9ORF72 as a pathogenic mechanism but rather suggest toxic gain-of-function mechanisms. Indeed, studies using patient-derived iPSNs together with transfected cells as well as Drosophila and zebrafish animal models strongly suggest that expression of G 4 C 2 repeats causing length-dependent formation of intranuclear RNA foci can directly and progressively trigger cellular toxicity. RNA foci formation is accompanied by hnRNP and RBP sequestration, including hnRNPH which binds to and colocalise with G 4 C 2 repeats [28, 36] (Table 1) . RNA foci formation is accompanied by transcriptional alterations and appears to correlate with disease-related apoptotic cell death [28] . These findings are of particular interest since mutations within and subsequent dysfunction of hnRN-PA2B1 and hnRNPA1 have been shown to cause multisystem proteinopathy and ALS [25] , suggesting that G 4 C 2 -mediated sequestration and functional depletion of hnRNPs are cytotoxic and thus directly contribute to disease [28] .
Concomitant to RNA foci and subsequent RBP sequestration, several potential pathways impacted by the presence of hexanucleotide repeats have been identified which cause neuronal dysfunction including the misregulation of genes such as DPP6, KCNQ3, CBLN1, CBLN2 and CBLN4 which are collectively involved in synapse formation and the regulation of neuronal excitability [45] . Moreover, modelling C9ORF72 hexanucleotide repeat expansion also revealed unambiguous evidence that RAN translation of hexanucleotide repeats longer than 30-40 repeats can lead to sense and antisense DPRs that are able to form cytoplasmic aggregates, likely conferring cellular toxicity comparable to other proteinopathies. These studies in cell and animal models therefore identify RNA toxicity, RBP sequestration and accumulation of DPRs as emerging pathogenic pathways underlying C9 ALS/FTLD. These pathways have also been implicated in other repeat expansion diseases, including DM1&2 and FXTAS, suggesting that they represent common pathogenic mechanisms underlying repeat-associated neurodegeneration [14] .
In DM1, DM2 and FXTAS, the pathogenic function of repeat-expanded RNA arises from the formation of nuclear RNA foci [33, 54] , the sequestration of RBPs into these foci [49] and RAN translation into repeat-derived proteins [13] . Foci-bound RBPs are unable to regulate RNA processing, thereby affecting cellular viability [49] . This phenomenon is well described in DM1, where 3′UTR CTG expansion in DMPK promotes nuclear foci formation and sequestration of RBPs, such as muscleblind-like (MBNL), that are involved in RNA splicing [33, 49] . MBNL sequestration is also responsible for toxicity in DM2, a disease in which very similar symptoms result from CCTG expansion in intron 1 of zinc finger 9 (ZNF9) [42] . In FXTAS, a CGG repeat expansion between 50 and 200 repeats leads to foci formation and sequestration of Pur-alpha and hnRNP A2/B1 [24, 49] , which are also found to be sequestered into G 4 C 2 RNA foci. Moreover, RAN translation of CGG repeats in the 5′-UTR of the FMR1 leads to a polyglycinecontaining protein, FMRpolyG, which has been shown to accumulate in ubiquitin-positive inclusions in Drosophila, cell culture, mouse models, as well as in FXTAS patient brains [50] . Interestingly, this study also showed that in Drosophila, CGG repeat toxicity could be suppressed by eliminating RAN translation [50] .
These data suggest that formation of RNA foci, RBP sequestration and resultant defects in RNA processing as well as accumulation of RAN translation products appear to be common mechanisms for nucleotide repeat-associated neurodegenerative diseases, including C9ORF72 hexanucleotide repeat expansion in ALS and FTLD.
Conclusions and future directions
Studies in cell and animal models have provided initial insights into the pathogenic mechanisms underlying G 4 C 2 repeat expansion and have identified RNA toxicity, RBP sequestration and accumulation of DPRs as potential pathogenic pathways underlying C9 ALS/FTLD (Fig. 2) . These studies provide a framework for further investigations, for which many questions remain. How does ageing and stress contribute to RNA toxicity, DPR accumulation and aggregation? How does RBP sequestration and accumulation of DPRs trigger apoptosis? How is TDP-43 pathology implicated? Repeat expansion in C9ORF72 is always associated with TDP-43 proteinopathy, the major inclusion protein in ALS and FTLD, but TDP-43 does not bind G 4 C 2 repeats, nor has it been detected in G 4 C 2 RNA foci. Instead, hnRNPs and several RBPs are known to bind TDP-43 [30] , which might represent a functional link between G 4 C 2 repeat expansion and TDP-43 proteinopathy seen in the majority of FTLD and ALS cases. Is TDP-43 mislocalisation therefore mechanistic in and/or with G 4 C 2 repeatmediated toxicity? In fact understanding the link between expanded hexanucleotide repeats and TDP-43 pathology could help unravel mechanisms capable of causing neurodegeneration across the broad spectrum of ALS-FTLD. Hence, answers to these questions are urgently needed to better understand disease initiation and progression, and to identify therapeutic targets and strategies for the treatment of ALS and FTLD.
